TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02730416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib or Placebo; Carboplatin, Paclitaxel
Description: Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nintedanib or Placebo; Carboplatin, Paclitaxel
Description: Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
Study: NCT02677337

Intervention type: OTHER
Group type: OTHER
Intervention: chart abstraction
Description: chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
Study: NCT01020019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol: 20 mg/TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Lofex: .6 mg/ TID
Study: NCT01121211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone 300mcg transdermal patch x 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patch x 24 weeks
Study: NCT00861211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: senicapoc
Description: Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
Study: NCT02677337

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Program
Study: NCT02988310

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT00956813

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT00861211

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT03536039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: dose of 0.8 mcg/sqm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RITUXIMAB
Description: dose of 375 mg/mq

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: dose of 50 mg/mq

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: dose of 750 mg/mq

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: dose of 1.4 mg/mq (max 2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 75 mg
Study: NCT03940742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT00709904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Semuloparin sodium)
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily
Study: NCT03640676

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FlowOx
Description: FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlowOx
Description: FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
Study: NCT03306264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen
Description: Decitabine 20 mg/m\^2 one-hour IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen
Description: Decitabine 20 mg/m\^2 one-hour IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen
Description: Decitabine 20 mg/m\^2 one-hour IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen
Description: Decitabine 20 mg/m\^2 one-hour IV infusion
Study: NCT00709904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily
Study: NCT04137926

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MicRNAs battery
Description: for MCI due to AD diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MicRNAs battery
Description: for MCI due to AD diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MicRNAs battery
Description: for MCI due to AD diagnosis
Study: NCT00448929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OculusGen Biodegradable Collagen Matrix Implant
Description: Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
Study: NCT03861689

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI pelvis
Description: MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
Study: NCT00928629

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ankle-brachial index (ABI) Screening Test
Description: Patients will undergo an ABI measurement
Study: NCT03727113

Intervention type: PROCEDURE
Intervention: Optimization cohort
Description: Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.

Intervention type: PROCEDURE
Intervention: Control cohort
Description: Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
Study: NCT03011385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Planning
Description: Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Planning
Description: Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Planning
Description: Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
Study: NCT03026621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lignite Extract
Description: The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Herbal tea
Description: This is an herbal tea that will look like the control
Study: NCT03011385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
Study: NCT03251248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11455
Description: Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11455
Description: Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
Study: NCT03306888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Coaching
Description: Physical activity coaching over 4 months
Study: NCT01211275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: axitinib
Description: axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
Study: NCT04510935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: the patient will receive general anesthesia during surgery in this group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: the patient will receive local anesthesia during surgery in this group.
Study: NCT03528434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 10mg dispersible zinc sulfate tablet
Study: NCT01862679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-flux haemodialysis
Description: High-flux haemodialysis is the standard dialysis modality currently in use in the UK
Study: NCT03528434

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispersible tablet with inert ingredients, identical to zinc in appearance
Study: NCT00333606

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Body acupuncture of 1 specific point per trial session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Body acupuncture of 1 specific point per trial session
Study: NCT01862679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-flux haemodialysis
Description: High-flux haemodialysis is the standard dialysis modality currently in use in the UK

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration
Description: During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration
Description: During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood.
Study: NCT03282552

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula High Flow Oxygen
Description: Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula High Flow Oxygen
Description: Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
Study: NCT00653354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib/placebo
Description: valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
Study: NCT03291613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinpoint App
Description: Tablet app with pain assessment and communication education, and pain assessment tool.
Study: NCT01155895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate / Benazepril Hydrochloride
Description: 10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate / Benazepril Hydrochloride
Description: 10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
Study: NCT00658112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide
Description: Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
Study: NCT01027169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safinamide
Description: single dose of 50mg safinamide on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safinamide
Description: single dose of 50mg safinamide on Day 1
Study: NCT06048471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HiTop
Description: High tone transcutaneous electrical stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: HiTop
Description: High tone transcutaneous electrical stimulation
Study: NCT00014235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT01027169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safinamide
Description: single dose of 50mg safinamide on Day 1
Study: NCT00014235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study: NCT00556842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemi-arthroplasty
Description: Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
Study: NCT03673137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
Study: NCT02210429

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elbow Fracture Fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elbow Fracture Fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elbow Fracture Fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elbow Fracture Fixation
Study: NCT03673137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible electroporation
Description: During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
Study: NCT02396238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution Device
Description: ADRCs prepared using the investigational Celution Device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00294190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.